Literature DB >> 16774814

In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates.

M Tato1, E Gómez-G de la Pedrosa, R Cantón, I Gómez-García, J Fortún, P Martín-Davila, F Baquero, E Gomez-Mampaso.   

Abstract

The activity of linezolid was studied against 55 Mycobacterium tuberculosis (42 susceptible, 3 isoniazid resistant and 10 isoniazid and rifampicin resistant), one Mycobacterium bovis and two multidrug-resistant M. bovis isolates using the standard 7H10 agar proportion and the ESP Culture System II methods. Both methods displayed similar MIC(90) values (minimum inhibitory concentrations for 90% of the organisms) of 0.5mg/L; however, the former method yielded slightly lower MIC(50) values (MICs for 50% of the organisms) (0.25mg/L) compared with the latter method (0.5mg/L). No differences were observed between susceptible and resistant isolates, including multidrug-resistant M. bovis isolates, with a MIC range of 0.12-0.5mg/L. The potential role of linezolid in tuberculosis patients requires further in vivo evaluation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16774814     DOI: 10.1016/j.ijantimicag.2006.02.011

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  10 in total

1.  Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis.

Authors:  Bryan McGee; Reynaldo Dietze; David Jamil Hadad; Lucilia Pereira Dutra Molino; Ethel Leonor Noia Maciel; W Henry Boom; Moises Palaci; John L Johnson; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

2.  Genome-wide expression profiling of the response to linezolid in Mycobacterium tuberculosis.

Authors:  Junchao Liang; Xudong Tang; Na Guo; Kaiyu Zhang; Aizhen Guo; Xiuping Wu; Xuelin Wang; Zhenhong Guan; Lihui Liu; Fengge Shen; Mingxun Xing; Liqiang Liu; Lei Li; Lu Yu
Journal:  Curr Microbiol       Date:  2012-03-03       Impact factor: 2.188

3.  In Vitro and In Vivo Activity of Oxazolidinone Candidate OTB-658 against Mycobacterium tuberculosis.

Authors:  Shaochen Guo; Bin Wang; Lei Fu; Xi Chen; Weiyan Zhang; Haihong Huang; Yu Lu
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

4.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Authors:  Myungsun Lee; Jongseok Lee; Matthew W Carroll; Hongjo Choi; Seonyeong Min; Taeksun Song; Laura E Via; Lisa C Goldfeder; Eunhwa Kang; Boyoung Jin; Hyeeun Park; Hyunkyung Kwak; Hyunchul Kim; Han-Seung Jeon; Ina Jeong; Joon Sung Joh; Ray Y Chen; Kenneth N Olivier; Pamela A Shaw; Dean Follmann; Sun Dae Song; Jong-Koo Lee; Dukhyoung Lee; Cheon Tae Kim; Veronique Dartois; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

5.  Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis.

Authors:  Reynaldo Dietze; David Jamil Hadad; Bryan McGee; Lucilia Pereira Dutra Molino; Ethel Leonor Noia Maciel; Charles A Peloquin; Denise F Johnson; Sara M Debanne; Kathleen Eisenach; W Henry Boom; Moises Palaci; John L Johnson
Journal:  Am J Respir Crit Care Med       Date:  2008-09-11       Impact factor: 21.405

6.  Successful Treatment of Disseminated Bacillus Calmette-Guérin Disease in an HIV-Infected Child with a Linezolid-Containing Regimen.

Authors:  Srđan Roglić; Drusia Dickson; Branko Miše; Klaudija Višković; Vera Katalinić-Janković; George Rutherford; Josip Begovac
Journal:  Case Rep Infect Dis       Date:  2016-10-10

7.  Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.

Authors:  Andreas H Diacon; Veronique R De Jager; Rodney Dawson; Kim Narunsky; Naadira Vanker; Divan A Burger; Daniel Everitt; Frances Pappas; Jerry Nedelman; Carl M Mendel
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

8.  Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis.

Authors:  Marjorie Z Imperial; Jerry R Nedelman; Francesca Conradie; R M Savic
Journal:  Clin Infect Dis       Date:  2022-05-30       Impact factor: 20.999

9.  Multidrug- and extensively drug-resistant tuberculosis, Germany.

Authors:  Barbara Eker; Johannes Ortmann; Giovanni B Migliori; Giovanni Sotgiu; Ralf Muetterlein; Rosella Centis; Harald Hoffmann; Detlef Kirsten; Tom Schaberg; Sabine Ruesch-Gerdes; Christoph Lange
Journal:  Emerg Infect Dis       Date:  2008-11       Impact factor: 6.883

10.  Antimycobacterial Activity of Laurinterol and Aplysin from Laurencia johnstonii.

Authors:  Sara García-Davis; Karla Leal-López; Carmen A Molina-Torres; Lucio Vera-Cabrera; Ana R Díaz-Marrero; José J Fernández; Pilar Carranza-Rosales; Ezequiel Viveros-Valdez
Journal:  Mar Drugs       Date:  2020-05-30       Impact factor: 5.118

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.